Introduction {#s1}
============

Salivary gland tumors are heterogeneous group of uncommon tumors. They are predominantly benign. Malignant tumors of salivary gland comprise less than 1% of all cancers of head and neck \[[@R01]\]. Salivary gland malignancy (SGM) may occur as a primary malignancy or as a second malignancy in people with prior history of other neoplasms. Increased risk of SGM in people with benign salivary gland tumors, Hodgkin's lymphoma, medulloblastoma and basal cell carcinoma has been reported \[[@R02]-[@R05]\]. This may be related to the genetic predisposition to malignancy or to the associated treatments like radiation exposure. The risk and characters of such secondary salivary gland malignancy (sSGM) in patients with primary thyroid cancer has, however, not been evaluated before. In the present study, we used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database of well-differentiated thyroid cancer (WTC) patients to determine the risk of sSGM compared to general population.

Methods {#s2}
=======

We identified all cases of WTC diagnosed between 1973 - 2014 from the SEER 18 registry using the following International Classification of Disease for Oncology, 3rd edition (ICD-O-3) codes: 8330/3, 8331/3, 8332/3, 8335/3, 8340/3, 8341/3, 8342/3, 8343/3 and 8344/3. We excluded cases diagnosed at autopsy and those lost to follow-up. Using the Warren and Gates criteria as modified by National Cancer Institute, sSGM was defined as a metachronous salivary gland malignancy developing at least 6 months after the diagnosis of WTC \[[@R06], [@R07]\]. Patients were followed up from the time of diagnosis of WTC to the date of last known vital status, death or the last point of data collection. We used multiple primary standardized incidence ratio session of the SEER\*Stat software (version 8.3.4 - March 23, 2017) to calculate standardized incidence ratio (SIR) and excess risk (ER) of sSGM for WTC patients. Confidence intervals and P-values were calculated using Poisson exact methods for the ratio of observed to expected events. Separately, all cases of primary salivary gland malignancy (pSGM) diagnosed between 1973 - 2014 were extracted from the SEER 18 registry using the following International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD10) codes: C07.9, C08.0, C08.1, C08.8 and C08.9. The different characteristics between pSGM and sSGM were compared using independent samples *t*-test for continuous variables and Chi-square tests for categorical variables.

Results {#s3}
=======

There were a total of 68,339 patients with primary WTC in SEER 18 registries. Of these, 18 patients developed sSGM with the observed to expected ratio (O/E) being 3.58 (95% CI: 2.12 to 5.65; P \< 0.05) and excess risk (ER) being 0.48 per 10,000 population ([Table 1](#T1){ref-type="table"}). The median age at diagnosis for sSGM was 55 years (range 22 - 81 years) with a median latency period of 39.5 months (range 5 - 97 months) from the time of diagnosis of thyroid cancer. The incidence of sSGM remained higher between 6 months to 10 years from the time of diagnosis of thyroid cancer.

###### Secondary Salivary Gland Malignancy in Patients With Thyroid Cancer

                                     Secondary salivary malignancy                           
  ---------------------------------- ------------------------------- ------- --------------- -------
  Total Cases                        18                              3.58    2.12 - 5.65     0.48
  Age                                                                                        
    \< 60 years                      12                              4.51    2.33 - 7.88     0.44
    ≥ 60 years                       6                               2.53    0.93 - 5.50     0.64
  Gender                                                                                     
    Male                             2                               1.13    0.14 - 4.07     0.04
    Female                           16                              4.91    2.80 - 7.97     0.59
  Race                                                                                       
    White                            13                              3.04    1.62 - 5.19     0.39
    Black                            2                               5.20    0.63 - 18.79    0.70
    Asian or Pacific Islander        3                               9.38    1.93 - 27.41    1.18
  Grade of thyroid malignancy                                                                
    I - well differentiated          7                               9.70    3.90 - 19.98    1.56
    II - moderately differentiated   0                               0.00    0.00 - 19.54    -0.20
    III - poorly differentiated      1                               14.52   0.37 - 80.88    3.56
    IV - undifferentiated            0                               0.00    0.00 - 636.06   -0.24
    Unknown                          10                              2.47    1.18 - 4.54     0.27
  Radioactive iodine therapy                                                                 
    No RAI                           6                               2.18    0.80 - 4.74     0.23
    RAI                              12                              5.26    2.72 - 9.19     0.76
  Latency period                                                                             
    2 - 5 months                     1                               3.94    0.10 - 21.97    0.49
    6 - 11 months                    3                               8.25    1.70 - 24.10    1.21
    12 - 59 months                   9                               3.82    1.75 - 7.25     0.50
    60 - 119 months                  5                               3.11    1.01 - 7.25     0.42
    120+ months                      0                               0.00    0.00 - 8.18     -0.22

CI: confidence interval; O/E: observed to expected ratio; RAI: radioactive iodine.

The risk of developing sSGM in those with primary thyroid carcinoma as compared to those without primary thyroid carcinoma was significantly higher among the patients below 60 years of age with an O/E of 4.51 (95% CI: 2.33 - 7.88; P \< 0.05) and ER of 0.44 per 10,000 population. Similarly, the risk was higher among females (O/E: 4.91; 95% CI: 2.80 - 7.97; P \< 0.05) and whites (O/E: 3.04; 95% CI: 1.62 - 5.1 9; P \< 0.05). Furthermore, among the patients with well-differentiated thyroid carcinoma or among those treated with radioactive iodine (RAI), the incidence of sSGM was higher as compared to those without primary thyroid carcinoma with O/E of 9.70 (95% CI: 3.90 - 19.98; P \< 0.05) and 5.26 (95% CI: 2.72 - 9.19; P \< 0.05) respectively.

There were also 19,008 cases of pSGM in the registry. There was no difference in the mean age at diagnosis (59.80 ± 18.361 vs. 53.28 ± 16.634; P = 0.132) or the proportion of patients below 60 years of age (45.3% vs. 66.7%; P = 0.07) in the pSGM and sSGM groups ([Table 2](#T2){ref-type="table"}). There were a greater proportion of females developing sSGM than pSGM (88.9% vs. 46.1%; P \< 0.05). There was, however, no difference in the proportion of different races developing pSGM and sSGM. There was also no difference between the primary and secondary salivary gland malignancies (SGM) in either the proportion of the salivary gland involved or the grading of the tumor.

###### Characteristics of Primary and Secondary Salivary Gland Malignancy

                                                          Primary Salivary Malignancy   Secondary Salivary Malignancy                             
  ------------------------------------------------------- ----------------------------- ------------------------------- ----------------- ------- -----------
  Total cases                                             19,008                        \-                              18                \-      
  Age at diagnosis                                        59.80 ± 18.361)                                               53.28 ± 16.634)           P = 0.132
  Age group                                                                                                                                       P = 0.07
    \< 60 years                                           8,615                         45.3%                           12                66.7%   
    ≥ 60 years                                            10,393                        54.7%                           6                 33.3%   
  Gender                                                                                                                                          P \< 0.05
    Male                                                  10,240                        53.9%                           2                 11.1%   
    Female                                                8,768                         46.1%                           16                88.9%   
  Race                                                                                                                                            P = 0.51
    White                                                 15,630                        82.2%                           13                72.2%   
    Black                                                 1,656                         8.7%                            2                 11.1%   
    Other                                                 1,486                         7.8%                            3                 16.7%   
    Unknown                                               236                           1.2%                            0                 0%      
  Primary site                                                                                                                                    P = 0.48
    C07.9 - parotid gland                                 15,134                        79.6%                           17                94.4%   
    C08.0 - submandibular gland                           2,845                         15%                             0                 0%      
    C08.1 - sublingual gland                              184                           1.0%                            0                 0%      
    C08.8 - overlapping lesion of major salivary glands   20                            0.1%                            0                 0%      
    C08.9 - major salivary gland, NOS                     825                           4.3%                            1                 5.6%    
  Grade of salivary cancer                                                                                                                        P = 0.08
    I - well differentiated                               1,733                         9.1%                            4                 22.2%   
    II - moderately differentiated                        3,337                         17.5%                           5                 27.8%   
    III - poorly differentiated                           3,322                         17.5%                           1                 5.6%    
    IV - undifferentiated                                 1,487                         7.9%                            0                 0%      
    Unknown                                               9,129                         48%                             8                 44.4%   

Discussion {#s4}
==========

Thyroid cancer is the most common endocrine malignancy with an increasing incidence over the last few decades \[[@R08], [@R9]\]. It is a malignancy of the relatively young, the median age at diagnosis being 46 years \[[@R10]\]. More than 90% of thyroid cancers are of well-differentiated variety consisting of papillary carcinoma and follicular carcinoma, and the 10-year survival rate is estimated to be more than 90% with appropriate treatment \[[@R11]-[@R13]\]. This combination of young age at diagnosis and favorable prognosis leads to an increased incidence of subsequent secondary malignancies. Several studies have estimated the incidence of second primary malignancy in thyroid cancer to be 7-8% \[[@R14], [@R15]\]. This has been attributed to the genetic predisposition to malignancy and associated treatments like RAI or radiation therapy \[[@R16]-[@R18]\].

Malignant salivary gland tumors are rare, and comprise less than 1% of all cancers of head and neck \[[@R01]\]. The annual incidence of malignant tumors of major salivary glands varies between slightly greater than 0.05 and less than 2 per 100,000 \[[@R19]\]. The incidence, however, has been increasing in recent years in United States \[[@R20]\]. They tend to vary considerably in their anatomic site of origin and histology. Most of the SGM are adenocarcinomas of the parotid gland \[[@R01]\]. This is consistent with the findings in our study, where almost four-fifths of the patients with SGM involved the parotid gland. There was also no statistically significant difference in the site of origin of pSGM and sSGM, the parotid gland being most commonly involved in both. However, malignant tumors comprise only 25% of all tumors arising in the parotid gland as compared to up to 90% of sublingual gland tumors \[[@R21]\]. Majority of the tumors developing in minor salivary glands tends to be malignant as well. In our study, both pSGM and sSGM were of similar histological grades. Benign parotid gland tumors may rarely turn malignant \[[@R05]\]. Irradiation is also a known risk factor for SGM, as is a history of prior cancers like Hodgkin's lymphoma, medulloblastoma and basal cell carcinoma \[[@R02]-[@R04], [@R22]\]. While prior studies of SGM have reported equal sex distribution with majority of patients in sixth decade of life, there were a greater proportion of males and patients above 60 years of age in our study. There was, however, no statistical difference between pSGM and sSGM in terms of the age at diagnosis or the proportion of patients diagnosed before 60 years of age.

In our study, there was a statistically significant increase in the incidence of sSGM in patients with prior thyroid cancer. This was consistent with similar findings in other studies and pooled analyses \[[@R15], [@R23]\]. The increased risk of sSGM was seen between 6 months to 10 years from the time of diagnosis of thyroid cancer, and emphasizes the need for long-term surveillance in thyroid cancer survivors for SPM's. A greater risk of sSGM was seen with well-differentiated thyroid cancers. This may relate partly to well-differentiated variety being overwhelmingly the most common thyroid cancer and partly to its excellent prognosis enabling long enough survival for the development of sSGM. On a similar note, people who were below 60 years of age at the time of diagnosis of thyroid cancer were at greater risk of sSGM than general population. The risk of sSGM was also greater if the person was female or white. This may relate to the genetic predisposition of these groups to develop salivary gland malignancy \[[@R01]\]. The risk of sSGM also increased significantly in patients receiving RAI therapy for their WTC. This finding is consistent with prior studies that showed increased incidence of SPM, including that of salivary gland malignancy, with RAI-treated thyroid cancers \[[@R15], [@R17]\]. Given the widespread use of RAI in thyroid cancer including the low grade ones, these findings warrant a more judicious approach in their use \[[@R24], [@R25]\].

Potential limitations of this study include a retrospective study design and an inability to verify the accuracy of coding. Similarly SEER program does not collect data on co-morbidities that may confound some of our findings. Despite these limitations, this study utilizes a real world data and is the largest study to specifically analyze the risk of sSGM in thyroid cancers.

In conclusion, patients with thyroid cancers are at an increased risk of developing sSGM than the general population. This risk is greater if the person is below 60 years of age, female, white, with well-differentiated thyroid carcinoma or is treated with RAI.
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